The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Biomarkers of response and resistance to antiangiogenic therapy
Open accessAbstract
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“no validated biomarkers are available to guide the use of antiangiogenic drugs7,126.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Flagged first, then by citations
1 of the 83 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 573
Acharya, S. S., & Kundu, C. N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102749 · Cited by 22
Kumar, S., Mokhtari, R. B., Oliveira, I. D., Islam, S. S., de Toledo, S. R. C., Yeger, H., & Baruchel, S. (2013) · Translational Oncology · doi:10.1593/tlo.13286 · Cited by 22
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
Whang‐Peng, J., Cheng, A., Hsu, C., & Chen, C. (2010) · Journal of Experimental & Clinical Medicine · doi:10.1016/s1878-3317(10)60016-2 · Cited by 22
Špaks, A., Svirina, D., Spaka, I., Jaunalksne, I., Breiva, D., Tracums, I., & Krievins, D. K. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1172111 · Cited by 22
Neovascularity as a prognostic marker in renal cell carcinoma
Bauman, T. M., Huang, W., Lee, M. H., & Abel, E. J. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.005 · Cited by 22
Clinical pharmacology of anti-angiogenic drugs in oncology
Gougis, P., Wassermann, J., Spano, J., Keynan, N., Funck‐Brentano, C., & Salem, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.010 · Cited by 24
Vallejo-Ardila, D. L., Fifis, T., Burrell, L. M., Walsh, K. A., & Christophi, C. (2018) · Oncotarget · doi:10.18632/oncotarget.26174 · Cited by 22
Konings, I. R. H. M., de Jonge, M. J. A., Burger, H., van der Gaast, A., Beijsterveldt, L. E. C. V., Winkler, H. J. S., Verweij, J., Yuan, Z., Hellemans, P., & Eskens, F. A. L. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605867 · Cited by 22
Obesity and leptin in breast cancer angiogenesis
Lagarde, C., Thapa, K., Cullen, N. M., Hawes, M. L., Salim, K., Benz, M. C., Dietrich, S. R., Burow, B. E., Bunnell, B. A., Martin, E. C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465727 · Cited by 22
Lowerison, M. R., Zhang, Y., Chen, X., Fan, T. M., & Song, P. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3119280 · Cited by 21
Garcia‐Manero, G., Tibes, R., Kadia, T. M., Kantarjian, H. M., Arellano, M. L., Knight, E., Xiong, H., Qin, Q., Munasinghe, W. P., Roberts-Rapp, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0242-6 · Cited by 21
A Systematic Literature Analysis of Correlative Studies in Low-Dose Metronomic Chemotherapy Trials
Cramarossa, G., Lee, E. K., Sivanathan, L., Georgsdottir, S., Lien, K., Santos, K. D., Chan, K., & Emmenegger, U. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.14.14 · Cited by 21
Metformin and Angiogenesis in Cancer - Revisited
Kannarkatt, J., Alkharabsheh, O. A., Tokala, H., & Dimitrov, N. V. (2016) · Oncology · doi:10.1159/000448175 · Cited by 21
Takano, S., Mashiko, R., Osuka, S., Ishikawa, E., Ohneda, O., & Matsumura, A. (2010) · Brain Tumor Pathology · doi:10.1007/s10014-010-0271-y · Cited by 21
Ueda, S., Kuji, I., Shigekawa, T., Takeuchi, H., Sano, H., Hirokawa, E., Shimada, H., Suzuki, H., Oda, M., Osaki, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098715 · Cited by 21
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer
Singh, N., Badrun, D., & Ghatage, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1775813 · Cited by 20
Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer
Luu, T. H., Frankel, P. H., Chung, C. T., Chow, W. A., Mortimer, J. E., Hurria, A., & Somlo, G. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.013 · Cited by 20
Bertolini, F., Marighetti, P., & Shaked, Y. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.05.004 · Cited by 20
Starlinger, P. P., Brugger, P., Reiter, C. G., Schauer, D., Sommerfeldt, S., Tamandl, D., Kuehrer, I., SCHOPPMANN, S. F., Gnant, M., & Brostjan, C. (2011) · Neoplasia · doi:10.1593/neo.11916 · Cited by 20
Yamada, K. H., Kang, H., & Malik, A. B. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.09.010 · Cited by 19
Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
Subudhi, S., Lee, S., & Jain, R. K. (2026) · Cell · doi:10.1016/j.cell.2026.03.016 · Cited by 26
Self-citationGekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor
Zhang, S.-X., Zhu, C., Ba, Y., Chen, D., Zhou, X.-L., Cao, R., Wang, L.-P., Ren, Y., & Wu, X.-Z. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321521 · Cited by 19
Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year
Gross‐Goupil, M., Massard, C., & Ravaud, A. (2011) · Current Urology Reports · doi:10.1007/s11934-011-0232-y · Cited by 19
Lo, G., Zahrani, H. A., Jang, H. J., Menezes, R. J., Hudson, J. M., Burns, P. N., McNamara, M. G., Kandel, S. M., Khalili, K., Knox, J. J., et al. (2016) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2016.01.025 · Cited by 19
Non‐invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts
Walker‐Samuel, S., Boult, J. K. R., McPhail, L. D., Box, G., Eccles, S. A., & Robinson, S. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26112 · Cited by 19
Alam, F., Al-Hilal, T. A., Chung, S. W., Park, J., Mahmud, F., Seo, D.-H., Kim, H. S., Lee, D. S., & Byun, Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.009 · Cited by 19
Bevacizumab and breast cancer: current therapeutic progress and future perspectives
Yang, S. X. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.153 · Cited by 19
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
Raja, F. A., Hook, J., & Ledermann, J. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.009 · Cited by 18
The Role of Pharmacogenetics and Advances in Gene Therapy in the Treatment of Diabetic Retinopathy
Agarwal, A. K., Ingham, S. A., Harkins, K. A., Diana, V., & Nguyen, Q. D. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.173 · Cited by 19
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., & Ikeuchi, H. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821c44af · Cited by 18
Cheng, J., Wang, Y., Zhang, C.-F., Wang, H., Wu, W.-Z., Pan, F., Hong, N., & Deng, J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i11.1990 · Cited by 18
Anti-VEGF Therapy in Cancer: A Double-Edged Sword
Gardner, V., Madu, C. O., & Lu, Y. W. (2017) · InTech eBooks · doi:10.5772/66763 · Cited by 20
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer
Makondi, P. T., Lee, C., Huang, C., Chu, C., Chang, Y., & Wei, P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0189582 · Cited by 18
Yang, Y. A., Zhang, J., Zou, H., Shen, Y., Deng, S., & Wu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.49628 · Cited by 18
Vascular and Interstitial Biology of Tumors
Jain, R. K., Chauhan, V. P., & Duda, D. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00008-4 · Cited by 18
Self-citationAktaş, S. H., AKBULUT, H., YAZICI, O., Zengin, N., Akgun, N., Üstüner, Z., & İçlı, F. (2017) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1509-80 · Cited by 18
Influence of vascular endothelial growth factor on angiogenesis and neurogenesis
Rudko, A. S., Эфендиева, М. Х., Budzinskaya, M. V., & Karpilova, M. A. (2017) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2017133375-80 · Cited by 18
Anti–Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?
Schneider, B. P., & Sledge, G. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9266 · Cited by 18
Kaffas, A. E., Hoogi, A., Zhou, J., Durot, I., Wang, H., Rosenberg, J., Tseng, A., Sagreiya, H., Akhbardeh, A., Rubin, D. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63810-1 · Cited by 17
Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
Norton, K., Pandey, N. B., Han, Z., & Popel, A. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s65055 · Cited by 17
Endogenous Matrix-Derived Inhibitors of Angiogenesis
Sund, M., Nyberg, P., & Eikesdal, H. P. (2010) · Pharmaceuticals · doi:10.3390/ph3103021 · Cited by 17
Hayashi, H., Kurata, T., Fujisaka, Y., Kawakami, H., Tanaka, K., Okabe, T., Takeda, M., Satoh, T., Yoshida, K., Tsunoda, T., et al. (2012) · Cancer Science · doi:10.1111/cas.12034 · Cited by 17
Evolving strategies: future treatment of glioblastoma
Chamberlain, M. C. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.30 · Cited by 17
Sunitinib side effects as surrogate biomarkers of efficacy
Kollmannsberger, C. (2016) · Canadian Urological Association Journal · doi:10.5489/cuaj.4315 · Cited by 17
Metabolic effects of anti-angiogenic therapy in tumors
Zulato, E., Curtarello, M., Nardo, G., & Indraccolo, S. (2012) · Biochimie · doi:10.1016/j.biochi.2012.01.001 · Cited by 17
García‐Palmero, I., López‐Larrubia, P., Cerdán, S., & Villalobo, A. (2013) · NMR in Biomedicine · doi:10.1002/nbm.2918 · Cited by 17
Liu, Y., Wang, Z., Li, X., Ma, X., Wang, S., Kang, F., Yang, W., Ma, W., & Wang, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00888 · Cited by 17
Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
Vaios, E., Winter, S. F., Muzikansky, A., Nahed, B. V., & Dietrich, J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa031 · Cited by 17
Gaumann, A. K. A., Drexler, H. C. A., Lang, S. A., Stoeltzing, O., Diermeier‐Daucher, S., Buchdunger, E., Wood, J. M., Bold, G., & Breier, G. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2683 · Cited by 16
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
Jia, S., & Cai, J. (2016) · PubMed · Cited by 16
Makhoul, I., Klimberg, V. S., Korourian, S., Henry‐Tillman, R., Siegel, E. R., Westbrook, K. C., & Hutchins, L. F. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31828940c3 · Cited by 16
Brookes, K. E., Cummings, J., Backen, A. C., Greystoke, A., Ward, T. H., Jayson, G. C., & Dive, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605661 · Cited by 16
The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer
Fakih, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.20 · Cited by 17
Duda, D. G., Munn, L. L., & Jain, R. K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt114 · Cited by 16
Self-citationPantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., Chiplunkar, S. V., Duda, D. G., Gota, V., Gupta, S., et al. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.689 · Cited by 16
Self-citationAlić, L., van Vliet, M., Wielopolski, P. A., ten Hagen, T. L. M., van Dijke, C. F., Niessen, W. J., & Veenland, J. F. (2013) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1528 · Cited by 16
Safety Profile and Tolerability of Antiangiogenic Agents in Non–Small-Cell Lung Cancer
Gadgeel, S. M. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.006 · Cited by 16
Al‐Zeheimi, N., Naik, A., Bakheit, C. S., Riyami, M. A., Ajarrah, A. A., Badi, S. A., Al-Baimani, K. S., Malik, K. A., Al-Habsi, Z., Al-Moundhri, M. S., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00323 · Cited by 16
Goldstein, R., Pickering, L. M., & Larkin, J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.134 · Cited by 15
Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm
Chu, B. F., & Otterson, G. A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.020 · Cited by 15
Targeting angiogenesis in gastrointestinal tumors: current challenges
Nandikolla, A. G., & Rajdev, L. N. (2016) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2016.08.04 · Cited by 16
Emmenegger, U., Chow, A., & Bocci, G. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_11 · Cited by 14
Grkovski, M., Emmas, S.-A., & Carlin, S. D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190892 · Cited by 14
Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy
Jaiprasart, P., Dogra, S., Neelakantan, D., Devapatla, B. K., & Woo, S. (2020) · Oncotarget · doi:10.18632/oncotarget.27307 · Cited by 14
Vaklavas, C., Roberts, B. S., Varley, K. E., Lin, N., Liu, M., Rugo, H. S., Puhalla, S., Nanda, R., Storniolo, A. M., Carey, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01258-x · Cited by 14
Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer
Yu, C. Y., & Mitrofanova, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.687813 · Cited by 14
Ma, R., Yang, Q., Cao, S., Liu, S., Cao, H., Xu, H., Wu, J., & Feng, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239252 · Cited by 13
Anti-angiogenic therapies for malignant pleural mesothelioma
Ceresoli, G. L., & Zucali, P. A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.681641 · Cited by 13
Mitigation of acute radiation-induced brain injury in a mouse model using anlotinib
Gao, X., Zheng, J., Ma, L., Ma, L., Zhai, Y., Yang, F., Wang, S., Fan, Q.-S., Wen, J., Wang, H., et al. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2284 · Cited by 13
Sharan, S., & Woo, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00033 · Cited by 13
Kim, Y.-E., Joo, B., Park, M., Shin, S. J., Ahn, J. B., & Kim, M. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.374 · Cited by 13
Tissue and Soluble Biomarkers in Breast Cancer and Their Applications: Ready to Use?
Danova, M., Delfanti, S., Manzoni, M., & Mariucci, S. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr023 · Cited by 13
Diagnostics of brain tumor in the early stage: current status and future perspectives
Ijaz, M., Hasan, I., Aslam, B., Yan, Y., Zeng, W., Gu, J., Jin, J., Zhang, Y., Wang, S., Xing, L., et al. (2025) · Biomaterials Science · doi:10.1039/d4bm01503g · Cited by 18
CXCR7 expression disrupts endothelial cell homeostasis and causes ligand-dependent invasion
Totonchy, J. E., Clepper, L., Phillips, K. G., McCarty, O. J. T., & Moses, A. V. (2014) · Cell Adhesion & Migration · doi:10.4161/cam.28495 · Cited by 12
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic
Hatch, A. J., Clarke, J. M., Nixon, A. B., & Hurwitz, H. I. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000129 · Cited by 12
Ghorab, M. M., Alsaid, M. S., Nissan, Y. M., Ashour, A. E., Al-Mishari, A. A., Kumar, A., & Ahmed, S. F. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00614 · Cited by 12
Muggia, F. M. (2012) · Drugs · doi:10.2165/11633510-000000000-00000 · Cited by 12
Posttreatment Evaluation of Central Nervous System Gliomas
Shiroishi, M. S., Booker, M. T., Agarwal, M. A., Jain, N., Naghi, I., Lerner, A., & Law, M. (2013) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2013.02.004 · Cited by 12
Shin, K. K., Lee, A. L., Kim, J. Y., Lee, S. Y., Bae, Y. C., & Jung, J. S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.040 · Cited by 12
Growth properties of SF188/V+ human glioma in rats in vivo observed by magnetic resonance imaging
Grossman, R., Tyler, B., Brem, H., Eberhart, C. G., Wang, S., Fu, D.-X., Wen, Z., & Zhou, J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0974-5 · Cited by 12
Farzam, P., Johansson, J., Mireles, M., Jiménez-Valerio, G., Martínez‐Lozano, M., Choe, R., Casanovas, O., & Durduran, T. (2017) · Biomedical Optics Express · doi:10.1364/boe.8.002563 · Cited by 12
Novel therapeutic strategies to target RCAS1, which induces apoptosis via ectodomain shedding.
Sonoda, K. (2011) · PubMed · doi:10.14670/hh-26.1475 · Cited by 12
CD133-containing microvesicles promote colorectal cancer progression by inducing tumor angiogenesis
Kim, B., Kim, S., Park, S., & Ko, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29292 · Cited by 11
Wang, N., Gaddam, S., Xie, Y., Christodoulou, A., Wu, C., Ma, S., Fan, Z., Wang, L., Lo, S. K., Hendifar, A. E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1007134 · Cited by 11
Marien, K. M., Croons, V., Martinet, W., Loof, H. D., Ung, C., Waelput, W., Scherer, S. J., Kockx, M. M., & Meyer, G. R. Y. D. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.993972 · Cited by 11
Grierson, R., Meyer-Rüsenberg, B., Kunst, F., Berna, M. J., Richard, G. W., & Thill, M. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0013 · Cited by 11
Previs, R. A., Armaiz-Peña, G. N., Lin, Y. G., Davis, A. N., Pradeep, S., Dalton, H. J., Hansen, J. M., Merritt, W. M., Nick, A. M., Langley, R. R., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0630 · Cited by 11
Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment
Sharma, S., Mann, A. P., Mölder, T., Kotamraju, V. R., Mattrey, R. F., Teesalu, T., & Ruoslahti, E. I. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.006 · Cited by 11
Jain, R. K., Martin, J. D., Chauhan, V. P., & Duda, D. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00008-6 · Cited by 14
Self-citationWang, N., Xie, Y., Fan, Z., Ma, S., Saouaf, R., Guo, Y., Shiao, S. L., Christodoulou, A., & Li, D. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28633 · Cited by 11
Fokas, E., Kamlah, F., Hänze, J., Engenhart‐Cabillic, R., Rose, F., & An, H. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00029.x · Cited by 11
Raja, A. M., Xu, S., Sun, W., Zhou, J., Tai, D., Chen, C.-S., Rajapakse, J. C., So, P. T. C., & Yu, H. (2010) · Journal of Biomedical Optics · doi:10.1117/1.3497565 · Cited by 11
Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice
Meehan, B., Garnier, D., Dombrovsky, A., Lau, K., D’Asti, E., Magnus, N., & Rak, J. W. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.07.003 · Cited by 11
Vollmuth, P., Karschnia, P., Sahm, F., Park, Y. W., Ahn, S. S., & Jain, R. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0983 · Cited by 10
Self-citationTowards defining biomarkers indicating resistances to targeted therapies
Stehle, F., Schulz, K., & Seliger, B. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.11.006 · Cited by 10
Sunitinib for Metastatic Renal Cell Carcinoma
Mukherji, D., Larkin, J., & Pickering, L. M. (2010) · Future Oncology · doi:10.2217/fon.10.94 · Cited by 10
Lemasson, B., Bouchet, A., Maisin, C., Christen, T., Duc, G. L., Remy, C. C., Barbier, E., & Serduc, R. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3357 · Cited by 10
Targeting angiogenesis in lung cancer - Pitfalls in drug development.
Hilbe, W., Manegold, C., & Pircher, A. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.01.01 · Cited by 10
Sharan, S., & Woo, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.36 · Cited by 10
Ferrara, N. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx067 · Cited by 10
Metadata
- Authors
- Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
- Affiliations
- Harvard University (US)
- Duke Medical Center (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-06
- Volume
- 6
- Issue
- 6
- Pages
- 327-338
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC3057433
- OpenAlex
- W1993016882
- Cited by
- 572
- References
- 83
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
- National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
